Edition:
India

Edwards Lifesciences Corp (EW.N)

EW.N on New York Stock Exchange

195.46USD
1:32am IST
Change (% chg)

$1.45 (+0.75%)
Prev Close
$194.01
Open
$194.17
Day's High
$196.18
Day's Low
$193.17
Volume
271,007
Avg. Vol
356,486
52-wk High
$197.30
52-wk Low
$134.53

Select another date:

Tue, Jul 2 2019

FDA ties three deaths to Edwards Lifesciences' recalled heart devices

The U.S. Food and Drug Administration said on Monday three deaths had been reported related to Edwards Lifesciences Corp's recall of some of its heart devices.

UPDATE 2-FDA ties three deaths to Edwards Lifesciences' recalled heart devices

July 1 The U.S. Food and Drug Administration said on Monday three deaths had been reported related to Edwards Lifesciences Corp's recall of some of its heart devices.

FDA says three deaths related to Edwards Lifesciences' recalled heart devices

July 1 The U.S. Food and Drug Administration said on Monday three deaths had been reported related to Edwards Lifesciences Corp's recall of some of its heart devices.

Edwards, Medtronic heart valve systems prove worth in low-risk patients: studies

Non-invasive heart valve replacement systems from Medtronic Plc and rival Edwards Lifesciences Corp proved as good or better than open heart surgery in younger, more active patients for whom the surgical option was deemed low risk, according to trial results that had been scheduled to be presented on Sunday.

Edwards, Medtronic heart valve systems prove worth in low-risk patients -studies

Non-invasive heart valve replacement systems from Medtronic Plc and rival Edwards Lifesciences Corp proved as good or better than open heart surgery in younger, more active patients for whom the surgical option was deemed low risk, according to trial results that had been scheduled to be presented on Sunday.

CORRECTED-Edwards, Medtronic heart valve systems prove worth in low-risk patients -studies

March 16 Non-invasive heart valve replacement systems from Medtronic Plc and rival Edwards Lifesciences Corp proved as good or better than open heart surgery in younger, more active patients for whom the surgical option was deemed low risk, according to trial results that had been scheduled to be presented on Sunday.

Edwards Lifesciences beats on revenue but forecast lags estimates

U.S. medical device maker Edwards Lifesciences narrowly topped Wall Street estimates for quarterly revenue on Thursday as it sold more heart monitors, but its outlook for March quarter earnings fell below analysts' forecasts.

Edwards Lifesciences beats on revenue but forecast lags estimates

Jan 31 U.S. medical device maker Edwards Lifesciences narrowly topped Wall Street estimates for quarterly revenue on Thursday as it sold more heart monitors, but its outlook for March quarter earnings fell below analysts' forecasts.

Select another date: